Monopar Therapeutics Inc. (MNPR) Income Statement Analysis

See more : The AES Corporation (AESC) Income Statement Analysis – Financial Results

Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Asante Incorporated (ASNXF) Income Statement Analysis – Financial Results
Everest Metals Corporation Ltd (EMC.AX) Income Statement Analysis – Financial Results
Ligitek Electronics Co.,Ltd (8111.TWO) Income Statement Analysis – Financial Results
Princess Private Equity Holding Limited (PEYS.L) Income Statement Analysis – Financial Results
Weidai Ltd. (WEIDY) Income Statement Analysis – Financial Results

Monopar Therapeutics Inc. (MNPR)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.monopartx.com

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	5.60M	7.59M	6.49M	4.07M	1.97M	1.77M	15.44M	280.36K	101.49K
General & Administrative	3.23M	2.95M	2.63M	2.44M	2.36M	1.63M	1.17M	912.47K	587.08K
Selling & Marketing	-3.23B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	3.23M	2.95M	2.63M	2.44M	2.36M	1.63M	1.17M	912.47K	587.08K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	14.50M	0.00	0.00
Operating Expenses	8.83M	10.54M	9.13M	6.51M	4.32M	3.40M	16.60M	1.19M	688.56K
Cost & Expenses	8.83M	10.54M	9.13M	6.51M	4.32M	3.40M	16.60M	1.19M	688.56K
Interest Income	429.04M	21.24K	24.02K	81.90K	98.89K	103.22K	48.26K	7.23K	1.25K
Interest Expense	0.00	0.00	0.00	0.00	0.00	103.22K	48.26K	7.23K	0.00
Depreciation & Amortization	8.83M	10.54M	9.13M	6.51M	4.32M	3.33M	2.10M	1.19M	688.56K
EBITDA	429.04K	0.00	0.00	0.00	0.00	0.00	-16.55M	8.03K	1.25K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-8.83M	-10.54M	-9.13M	-6.51M	-4.32M	-3.40M	-16.60M	-1.19M	-688.56K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	429.04K	21.24K	24.02K	204.30K	98.89K	31.15K	48.26K	8.03K	1.25K
Income Before Tax	-8.40M	-10.52M	-9.10M	-6.30M	-4.22M	-3.30M	-16.55M	-1.19M	-687.31K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-21.24K	-24.02K	-81.90K	-98.89K	-71.62K	-2.10M	800.00	-688.56K
Net Income	-8.40M	-10.49M	-9.08M	-6.22M	-4.13M	-3.23M	-16.55M	-1.19M	-687.31K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.58	-0.83	-0.73	-0.57	-0.39	-0.31	-1.59	-0.11	-0.06
EPS Diluted	-0.58	-0.83	-0.73	-0.57	-0.39	-0.31	-1.59	-0.11	-0.06
Weighted Avg Shares Out	14.51M	12.72M	12.47M	10.96M	10.59M	10.42M	10.42M	10.42M	10.59M
Weighted Avg Shares Out (Dil)	14.51M	12.72M	12.47M	10.96M	10.59M	10.42M	10.42M	10.42M	10.59M

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

December 5, 2024globenewswire.com

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical...

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

December 3, 2024globenewswire.com

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate...

3 Momentum Stocks Soaring Into 2025 and Beyond

December 3, 2024marketbeat.com

Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement...

What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'

December 2, 2024zacks.com

Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'

December 2, 2024zacks.com

Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

November 25, 2024seekingalpha.com

Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase...

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

November 8, 2024globenewswire.com

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

October 30, 2024globenewswire.com

WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously...

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

October 28, 2024globenewswire.com

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best...